Findings
Regulatory frameworks differ across regions, with the FDA focusing on digital health technologies and the EU emphasizing digital methodologies under MDR.
Determining whether a DHT qualifies as a medical device depends on its intended use and functionality, necessitating region-specific evaluations.
Health authority engagement can occur through FDA pathways like Critical Path Innovation Meetings (CPIM) and EMA’s Innovation Task Force (ITF).
Verification and validation of DHTs are crucial to ensure reliability and compliance with regulatory requirements in clinical trials.
Cybersecurity and compliance with privacy laws, such as GDPR, are mandatory considerations for DHT implementation.

Recommendations
Engage Regulators Early: Utilize FDA, EMA, or MHRA pathways (e.g., CPIM, ITF) during early development to align on requirements and mitigate risks.
Conduct thorough assessments to determine if a DHT qualifies as a medical device under regional regulations.
Implement robust validation and verification processes to confirm that DHTs are fit-for-purpose in clinical investigations.
Ensure compliance with GDPR, HIPAA, and other relevant data protection standards to safeguard patient information.
Adhere to GCP guidelines, including the ALCOA+ principles, to maintain data credibility and patient safety throughout the trial.

Regulatory Considerations
FDA Regulations: Evaluate DHTs under the FDA’s framework for medical devices, including exemptions under 21 CFR Part 812 and the Digital Health Software Precertification Program.
EU MDR/IVDR: Comply with MDR for medical devices and IVDR for in-vitro diagnostics, ensuring alignment with Annex VIII for software classification.
UK MHRA Guidance: Reference MHRA’s flowcharts for determining if a software qualifies as a medical device and ensure compliance with UK-specific regulatory requirements.
Global Harmonization Efforts: Consider global standards, such as ICH E6 (R2) and GHTF/IMDRF guidelines, to align multinational clinical trials.
Leverage pathways like EMA’s qualification process for novel methodologies and FDA’s DDT qualification program for broader acceptance of digital endpoints.